Bioextrax was founded in 2014 based on research at Lund University. The company develops a technology platform for production of environmentally friendly materials based on microbiology. The platform includes two main technologies: 1) Production of polyhydroxyalkanoates (PHA) – a bio-based plastic that can replace fossil-based plastic, and 2) Feather hydrolysis – a technology that converts feathers into hydrolyzed protein for animal feed and keratin microfibers as additives in various materials.
* The chemical company project seemingly back on track * The Chematur MoU converted into an agreement * We keep our fair value of SEK 3.7 per share Bioextrax reported Q1 2026 figures close to our estimates, with total revenues of KSEK 228 and an EBIT...
* Updates on Chematur, Konspec and the Candy producer * Lantmännen sparks hope for protein from feathers * We keep our fair value of SEK 3.7 per share Bioextrax reported an eventful Q4 2025, with EBIT of MSEK -5.0, slightly higher than expected. Cash...
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
* Regulatory evaluation successfully completed * Green light for the test panel to begin its work * We keep our fair value of SEK 3.7 per share Bioextrax recently communicated that the candy producer’s experts have completed their regulatory evaluation...
* Rights issue extends financial runway * Revenue from Konspec expected by Q2 2026 * Adjustments lead to a fair value of SEK 3.7 (4.23) per share Bioextrax once again reported figures close to our estimates in its recent Q3 report. Both revenues and ...
* Production increase from 100 to 300 tons of PHA per year from Konspec * Project with the chemical company delayed, exclusivity removed * We keep our fair value of SEK 4.23 per share Good news and bad news caused some turbulence in the share price of...
* Expecting agreements to materialise * Costs still in check * We keep our fair value to SEK 4.23 per share Bioextrax reported figures close to our estimates in its recent Q2 report. Revenues of MSEK 0.5 were slightly higher than expected, while costs...
* Expecting agreements to materialise * Costs still in check * We keep our fair value to SEK 4.23 per share In the Q1 report 2025, CEO Edvard Hall updated on current projects. Before the Q2 report in August, we expect some of the collaborations to advance...
* Several agreements approaching * Costs in line with expectations * We have adjusted our fair value to SEK 4.23 per share The reported figures in Bioextrax's recent Q4 report were close to our estimates. With no significant sales forecast, costs came...
* High interest amid progression of the projects * The rights issue in Q4 added MSEK 14.1 * We keep our fair value of SEK 7.60 per share Bioextrax has received numerous inquiries from research institutes and companies since the summer. At the same time...
[ingress] * Letter of intent with a leading chemical company * License agreement with Chematur Engineering regarding PHBV * We keep our fair value of SEK 7.60 per share During Q2, Bioextrax's project advanced. The company has entered into a license agreement...